CA2553290A1 - Reconnaissance de formes de proteines seriques pour le diagnostic ou le traitement d'etats physiologiques - Google Patents
Reconnaissance de formes de proteines seriques pour le diagnostic ou le traitement d'etats physiologiques Download PDFInfo
- Publication number
- CA2553290A1 CA2553290A1 CA002553290A CA2553290A CA2553290A1 CA 2553290 A1 CA2553290 A1 CA 2553290A1 CA 002553290 A CA002553290 A CA 002553290A CA 2553290 A CA2553290 A CA 2553290A CA 2553290 A1 CA2553290 A1 CA 2553290A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- mass spectrometry
- data
- profile
- database
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 102000004506 Blood Proteins Human genes 0.000 title claims abstract description 103
- 108010017384 Blood Proteins Proteins 0.000 title claims abstract description 103
- 238000003909 pattern recognition Methods 0.000 title claims abstract description 52
- 238000011282 treatment Methods 0.000 title claims abstract description 52
- 238000003745 diagnosis Methods 0.000 title claims description 5
- 238000004949 mass spectrometry Methods 0.000 claims abstract description 103
- 238000000034 method Methods 0.000 claims abstract description 45
- 201000010099 disease Diseases 0.000 claims abstract description 39
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 39
- 238000004422 calculation algorithm Methods 0.000 claims abstract description 18
- 238000012360 testing method Methods 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 43
- 238000004458 analytical method Methods 0.000 claims description 28
- 210000002966 serum Anatomy 0.000 claims description 23
- 210000001124 body fluid Anatomy 0.000 claims description 19
- 239000010839 body fluid Substances 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 13
- 239000008280 blood Substances 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 238000002560 therapeutic procedure Methods 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 7
- 210000002381 plasma Anatomy 0.000 claims description 6
- 210000004243 sweat Anatomy 0.000 claims description 6
- 210000002700 urine Anatomy 0.000 claims description 6
- 238000004891 communication Methods 0.000 claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 4
- 230000002685 pulmonary effect Effects 0.000 claims description 4
- 230000028327 secretion Effects 0.000 claims description 4
- 238000000539 two dimensional gel electrophoresis Methods 0.000 claims description 3
- 230000004962 physiological condition Effects 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims 3
- 230000007170 pathology Effects 0.000 abstract description 8
- 230000001575 pathological effect Effects 0.000 abstract description 5
- 238000007796 conventional method Methods 0.000 abstract description 4
- 238000010205 computational analysis Methods 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 description 13
- 229960001592 paclitaxel Drugs 0.000 description 13
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 13
- 206010060862 Prostate cancer Diseases 0.000 description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 241000725303 Human immunodeficiency virus Species 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 208000024827 Alzheimer disease Diseases 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 229960002656 didanosine Drugs 0.000 description 4
- NQHXCOAXSHGTIA-SKXNDZRYSA-N nelfinavir mesylate Chemical compound CS(O)(=O)=O.CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 NQHXCOAXSHGTIA-SKXNDZRYSA-N 0.000 description 4
- 238000011471 prostatectomy Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011472 radical prostatectomy Methods 0.000 description 3
- 229940064914 retrovir Drugs 0.000 description 3
- 229940023080 viracept Drugs 0.000 description 3
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229940039856 aricept Drugs 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229940108366 exelon Drugs 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- -1 urine Substances 0.000 description 2
- 229960002555 zidovudine Drugs 0.000 description 2
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960005230 nelfinavir mesylate Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
- G16B50/30—Data warehousing; Computing architectures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics
Landscapes
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Databases & Information Systems (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Evolutionary Biology (AREA)
- Bioethics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Software Systems (AREA)
- Evolutionary Computation (AREA)
- Epidemiology (AREA)
- Data Mining & Analysis (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Signal Processing (AREA)
- Molecular Biology (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/001579 WO2005080968A1 (fr) | 2004-01-20 | 2004-01-20 | Reconnaissance de formes de proteines seriques pour le diagnostic ou le traitement d'etats physiologiques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2553290A1 true CA2553290A1 (fr) | 2005-09-01 |
Family
ID=34887922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002553290A Abandoned CA2553290A1 (fr) | 2004-01-20 | 2004-01-20 | Reconnaissance de formes de proteines seriques pour le diagnostic ou le traitement d'etats physiologiques |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1711811A1 (fr) |
| CA (1) | CA2553290A1 (fr) |
| WO (1) | WO2005080968A1 (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2186031A4 (fr) * | 2007-07-23 | 2014-03-26 | Fio Corp | Procédé et système pour collecter, stocker, analyser et autoriser un accès à des données collectées et analysées associées à des sujets de tests biologiques et environnementaux |
| GB201114573D0 (en) * | 2011-08-23 | 2011-10-05 | Univ Sheffield Hallam | Categorisation of biological deposits using matrix assisted laser desorption ionisation mass spectrometry |
| KR20190062461A (ko) * | 2016-09-28 | 2019-06-05 | 미디얼 리서치 리미티드 | 의료 데이터 마이닝을 위한 시스템 및 방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6855554B2 (en) * | 2001-09-21 | 2005-02-15 | Board Of Regents, The University Of Texas Systems | Methods and compositions for detection of breast cancer |
-
2004
- 2004-01-20 CA CA002553290A patent/CA2553290A1/fr not_active Abandoned
- 2004-01-20 WO PCT/US2004/001579 patent/WO2005080968A1/fr not_active Ceased
- 2004-01-20 EP EP04703675A patent/EP1711811A1/fr not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005080968A1 (fr) | 2005-09-01 |
| EP1711811A1 (fr) | 2006-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Baxter et al. | Machine learning-based predictive modeling of surgical intervention in glaucoma using systemic data from electronic health records | |
| Saligan et al. | Supervised classification by filter methods and recursive feature elimination predicts risk of radiotherapy-related fatigue in patients with prostate cancer | |
| US20030154105A1 (en) | Systems and methods for obtaining data correlated patient samples | |
| Lindgren et al. | International stroke genetics consortium recommendations for studies of genetics of stroke outcome and recovery | |
| Yang et al. | Identifying cancer patients at risk for heart failure using machine learning methods | |
| Vollmuth et al. | Incremental value of serum neurofilament light chain and glial fibrillary acidic protein as blood-based biomarkers for predicting functional outcome in severe acute ischemic stroke | |
| CN113889221A (zh) | 重症肌无力患者他克莫司治疗剂量精准选择的系统及其应用 | |
| Terebelo et al. | Development of a prognostic model for overall survival in multiple myeloma using the Connect® MM Patient Registry | |
| WO2023128780A1 (fr) | Procédé de diagnostic précoce de maladies chroniques chez un patient | |
| Lv et al. | Early prediction of the 3-month outcome for individual acute ischemic stroke patients who received intravenous thrombolysis using the N2H3 nomogram model | |
| US20040096896A1 (en) | Pattern recognition of serum proteins for the diagnosis or treatment of physiologic conditions | |
| Ramon-Gonen et al. | Disease evolution and risk-based disease trajectories in congestive heart failure patients | |
| McDermott IV et al. | Novel association between opioid use and increased risk of retinal vein occlusion using the National Institutes of Health All of Us research program | |
| Singh et al. | Big data in oncology: Extracting knowledge from machine learning | |
| Jain et al. | Artificial intelligence for precision medicine and better healthcare | |
| CA2553290A1 (fr) | Reconnaissance de formes de proteines seriques pour le diagnostic ou le traitement d'etats physiologiques | |
| RU2515587C1 (ru) | Способ организации и ведения медицинского мониторинга | |
| CN118969081A (zh) | 肺癌基因的突变位置预测方法以及系统 | |
| Taddei et al. | Timing Is Everything: A Systematic Review of Optimal Repeat Computed Tomography Protocols in Traumatic Brain Injury | |
| MXPA06011525A (es) | Sistema y metodos para manejo del tratamiento y datos del paciente. | |
| WO2022244829A1 (fr) | Système d'administration d'informations biométriques, procédé d'administration d'informations biométriques, et programme d'administration d'informations biométriques | |
| Friedrich | Genomics and proteomics may help clinicians individualize cancer treatment | |
| Wu et al. | Derivation and validation of a risk index to predict all-cause mortality in type 2 diabetes mellitus | |
| Blanch et al. | Routinely collected health data to study inherited heart disease: a systematic review (2000–2016) | |
| Wang et al. | Machine learning-based MRI radiomics to predict postoperative complications following peripheral nerve sheath tumour excision |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |